Pharma industry returns on R&D investment hit 9-year low

LONDON (Reuters) - The cost of developing a new drug has nearly doubled since 2010 and the world's 12 biggest drugmakers are making the lowest return on their R&D investments in nine years, according to Deloitte. An annual survey of the economics of pharma research and development (R&D) by the consultancy found that despite a steady flow of new medicines reaching global markets, the 12 drugmakers' average return on their R&D fell to 1.9 percent this year, from 3.7 percent a year ago. The average cost of bringing a new medicine to market is now $2.18 billion, up from $1.19 billion back in 2010

Reuters December 19, 2018 06:05:11 IST
Pharma industry returns on R&D investment hit 9-year low

Pharma industry returns on RD investment hit 9year low

LONDON (Reuters) - The cost of developing a new drug has nearly doubled since 2010 and the world's 12 biggest drugmakers are making the lowest return on their R&D investments in nine years, according to Deloitte.

An annual survey of the economics of pharma research and development (R&D) by the consultancy found that despite a steady flow of new medicines reaching global markets, the 12 drugmakers' average return on their R&D fell to 1.9 percent this year, from 3.7 percent a year ago.

The average cost of bringing a new medicine to market is now $2.18 billion, up from $1.19 billion back in 2010.

Yet forecast peak sales for new medicines have halved over the same period to $408 million on average - a decline that reflects a growing focus on relatively small targeted patient groups, leading to multiple niche treatments.

"Despite the launch of many successful products, growing development costs and regulatory constraints are making it more difficult than ever for companies to redeem their R&D investment," said Deloitte consulting partner Colin Terry.

Overall, R&D returns are down by 8.2 percentage points since 2010, when they stood at 10.1 percent.

A group of younger and more specialised biotech companies analysed by Deloitte fared a lot better, with average returns of 9.3 percent, although this was still down from 12.5 percent in 2017.

The 12 big drugmakers tracked by Deloitte are Pfizer , Roche , Novartis , Sanofi , GlaxoSmithKline , Johnson & Johnson , AstraZeneca , Merck & Co , Eli Lilly , Bristol-Myers Squibb , Takeda <4502.T> and Amgen .

The four biotech companies are Biogen , Celgene , Gilead Sciences and AbbVie .

(Reporting by Ben Hirschler; Editing by Susan Fenton)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Israeli, UAE foreign ministers to meet in Germany on Tuesday
World

Israeli, UAE foreign ministers to meet in Germany on Tuesday

JERUSALEM (Reuters) - The foreign ministers of Israel and the United Arab Emirates will meet in Germany on Tuesday to discuss further steps in normalizing relations, officials said on Monday. Israel and the United Arab Emirates last month signed an agreement in Washington to normalise diplomatic ties and forge a broad new relationship.

Angry Birds maker Rovio's CEO leaving by mutual consent
News &amp; Analysis

Angry Birds maker Rovio's CEO leaving by mutual consent

By Anne Kauranen HELSINKI (Reuters) - The chief executive of Angry Birds games maker Rovio Entertainment said on Monday she would leave the company by mutual consent at the end of the year. Kati Levoranta has led Rovio since 2016 and took the company public in 2017

Microsoft to build hub for cloud services in Greece
News &amp; Analysis

Microsoft to build hub for cloud services in Greece

ATHENS (Reuters) - Microsoft Corp. is to build a data centre hub in Greece as it invests in cloud services infrastructure in the country, a boon to an economy weakened by a decade-long debt crisis and the coronavirus pandemic.